Report #2861531

Received Sep 25, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: NV
Recovered: Unknown
Vaccinated: —
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	1	—	IM

Symptoms (2)

Inappropriate schedule of product administrationNo adverse event

Symptom narrative

We had 6 Employees Who Have Received Their First Dose of Heplisav-B, But Are Anywhere From 2-8 Months Late In Receiving The Second Dose; Initial report received on 28-Aug-2025. A reported that a patient received HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization and the patient is late in receiving the second dose. No medical history or concomitant medications were reported. On an unknown date, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot number, expiration date, NDC number, route, and site not available)]. On 28-Aug-2025, after receiving HEPLISAV-B, the reporter noted that the patient, who is an employee, was 2-8 months late in receiving their second dose of HEPLISAV-B. No side effects were reported. Reporter declined to provide further information. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.